跳至主要内容
临床试验/NL-OMON48361
NL-OMON48361已完成不适用

An open-label, fixed sequence, crossover, 1-way drug­-drug-­interaction study between IMB-1018972 and each of repaglinide, midazolam, paroxetine, and fluvoxamine in healthy subjects - IMB-1018972 DDI study

Imbria Pharmaceuticals, Inc.0 个研究点目标入组 58 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
58

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Gender : male or female.
  • Part 1: 18 to 65 years, inclusive, at screening;
  • Parts 2 and 3: 25 to 65 years, inclusive, at screening.
  • 3. Body mass index : 18.0 to 32.0 kg/m2, inclusive, at screening.
  • 4. Status : healthy subjects.
  • Part 1: all races;
  • Parts 2 and 3: Caucasian only

排除标准

  • 1. Previous participation in the current study.
  • 2. Employee of PRA or the Sponsor.
  • 3. History of relevant drug and/or food allergies.
  • 4. Smoking more than 5 cigarettes, 1 cigar, or 1 pipe daily; the use of tobacco
  • products within 48 hours prior to admission to the clinical research center is
  • not allowed.
  • 5. History of alcohol abuse or drug addiction (including soft drugs like
  • cannabis products).

研究者

相似试验